Catecholaminergic Polymorphic Ventricular Tachycardia in Children
Author(s) -
Thomas M. Roston,
Jeffrey M. Vinocur,
Kathleen R. Maginot,
Saira Mohammed,
Jack C. Salerno,
Susan P. Etheridge,
Mitchell I. Cohen,
Robert M. Hamilton,
Andreas Pflaumer,
Ronald J. Kanter,
James E. Potts,
Martin J. LaPage,
Kathryn K. Collins,
Roman Gebauer,
Joel Temple,
Anjan S. Batra,
Christopher Erickson,
Maria MiszczakKnecht,
Peter Kubuš,
Yaniv BarCohen,
Michal J. Kantoch,
Vincent C. Thomas,
Gabriele Hessling,
Christopher M. Anderson,
MingLon Young,
Michel Cabrera Ortega,
Yung R. Lau,
Christopher L. Johnsrude,
Anne Fournier,
Prince J. Kannankeril,
Shubhayan Sanatani
Publication year - 2015
Publication title -
circulation arrhythmia and electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.684
H-Index - 102
eISSN - 1941-3149
pISSN - 1941-3084
DOI - 10.1161/circep.114.002217
Subject(s) - catecholaminergic polymorphic ventricular tachycardia , medicine , flecainide , interquartile range , ventricular tachycardia , cardiology , implantable cardioverter defibrillator , ventricular fibrillation , tachycardia , heart failure , sudden cardiac death , cohort , atrial fibrillation , ryanodine receptor 2 , ryanodine receptor , calcium
Catecholaminergic polymorphic ventricular tachycardia is an uncommon, potentially lethal, ion channelopathy. Standard therapies have high failure rates and little is known about treatment in children. Newer options such as flecainide and left cardiac sympathetic denervation are not well validated. We sought to define treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom